These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33349885)
1. Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis. Turner HC Int Health; 2020 Dec; 13(Suppl 1):S71-S74. PubMed ID: 33349885 [TBL] [Abstract][Full Text] [Related]
2. A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020). Turner HC; Ottesen EA; Bradley MH Parasit Vectors; 2022 May; 15(1):181. PubMed ID: 35643508 [TBL] [Abstract][Full Text] [Related]
3. Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis. Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Mante SD; Fitzpatrick C; Bradley MH Clin Infect Dis; 2017 Mar; 64(6):728-735. PubMed ID: 27956460 [TBL] [Abstract][Full Text] [Related]
4. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. Mathew CG; Bettis AA; Chu BK; English M; Ottesen EA; Bradley MH; Turner HC Clin Infect Dis; 2020 Jun; 70(12):2561-2567. PubMed ID: 31343064 [TBL] [Abstract][Full Text] [Related]
5. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. Gedge LM; Bettis AA; Bradley MH; Hollingsworth TD; Turner HC Parasit Vectors; 2018 Feb; 11(1):75. PubMed ID: 29391042 [TBL] [Abstract][Full Text] [Related]
7. Elimination of lymphatic filariasis as a public health problem in Malawi. Chiphwanya J; Mkwanda S; Kabuluzi S; Mzilahowa T; Ngwira B; Matipula DE; Chaponda L; Ndhlova P; Katchika P; Mahebere Chirambo C; Moses P; Kumala J; Chiumia M; Barrett C; Betts H; Fahy J; Rebollo Polo M; Reimer L; Stanton MC; Thomas B; Freer S; Molyneux DH; Bockarie MJ; Mackenzie CD; Taylor MJ; Martindale S; Kelly-Hope LA PLoS Negl Trop Dis; 2024 Feb; 18(2):e0011957. PubMed ID: 38363794 [TBL] [Abstract][Full Text] [Related]
8. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014). Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Ottesen EA; Bradley MH Infect Dis Poverty; 2016 May; 5(1):54. PubMed ID: 27388873 [TBL] [Abstract][Full Text] [Related]
9. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti. Antony Oliver MC; Graham M; Gass KM; Medley GF; Clark J; Davis EL; Reimer LJ; King JD; Pouwels KB; Hollingsworth TD Clin Infect Dis; 2024 Apr; 78(Supplement_2):S160-S168. PubMed ID: 38662697 [TBL] [Abstract][Full Text] [Related]
10. Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis. Devi RR; Raju V J Vector Borne Dis; 2018; 55(1):20-25. PubMed ID: 29916444 [TBL] [Abstract][Full Text] [Related]
11. Evolution of the monitoring and evaluation strategies to support the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis. Lammie PJ; Gass KM; King J; Deming MS; Addiss DG; Biswas G; Ottesen EA; Henderson R Int Health; 2020 Dec; 13(Suppl 1):S65-S70. PubMed ID: 33349883 [TBL] [Abstract][Full Text] [Related]
12. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. Hooper PJ; Chu BK; Mikhailov A; Ottesen EA; Bradley M PLoS Negl Trop Dis; 2014 Nov; 8(11):e3333. PubMed ID: 25411843 [TBL] [Abstract][Full Text] [Related]
13. The global programme to eliminate lymphatic filariasis: health impact after 8 years. Ottesen EA; Hooper PJ; Bradley M; Biswas G PLoS Negl Trop Dis; 2008 Oct; 2(10):e317. PubMed ID: 18841205 [TBL] [Abstract][Full Text] [Related]
14. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis. Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882 [TBL] [Abstract][Full Text] [Related]
15. Mass drug administration to eliminate lymphatic filariasis in India. Ramaiah KD; Das PK Trends Parasitol; 2004 Nov; 20(11):499-502. PubMed ID: 15471698 [TBL] [Abstract][Full Text] [Related]
16. Lymphatic Filariasis: A Systematic Review on Morbidity and Its Repercussions in Countries in the Americas. Medeiros ZM; Vieira AVB; Xavier AT; Bezerra GSN; Lopes MFC; Bonfim CV; Aguiar-Santos AM Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010576 [TBL] [Abstract][Full Text] [Related]
17. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Bockarie MJ; Deb RM Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694 [TBL] [Abstract][Full Text] [Related]
18. A game-theoretic model of lymphatic filariasis prevention. Rychtář J; Taylor D PLoS Negl Trop Dis; 2022 Sep; 16(9):e0010765. PubMed ID: 36137005 [TBL] [Abstract][Full Text] [Related]
19. A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. Riches N; Badia-Rius X; Mzilahowa T; Kelly-Hope LA PLoS Negl Trop Dis; 2020 May; 14(5):e0008289. PubMed ID: 32396575 [TBL] [Abstract][Full Text] [Related]
20. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007). Hooper PJ; Bradley MH; Biswas G; Ottesen EA Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]